JAPAN-SAKE-PR-SECRETARIA
25.7.2022 10:02:04 CEST | Business Wire | Press release
Japan Sake and Shochu Makers Association
(hereafter, “JSS") concluded a partnership agreement with the Association de la Sommellerie Internationale
(hereafter, “ASI”) in May this year.
JSS exchanged greetings at the ASI general assembly held at the “Nagoya Marriott Associa Hotel” in Japan on July 5 and 6, and joined the welcome dinner held the night before. There they had the opportunity to meet and greet representatives of sommelier associations from 22 countries who were visiting Japan. Welcome dinner cuisine was paired with wine and six varieties of Japanese sake.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005658/en/
ASI members were invited to a two-day excursion organized by Mie Sake Brewers Association on July 7 and 8. Participants had the valuable opportunity to tour sake breweries in Mie Prefecture, visit the Ise Grand Shrine that is known for its historical links to sake, and explore the rich history and techniques used to make dashi soup stock at katsuobushi (bonito flakes) production plants.
A sake tasting and discussion event with the member breweries of the Mie Sake Brewers Association, followed by the International Sake Conference in Mie
, were held in the evening of July 7 at the “Shima Kanko Hotel,” which attracted worldwide attention in 2016 as the venue for the G7 ISE-SHIMA SUMMIT. A panel discussion led by six panelists including ASI Chairman Wouters covered topics like the potential of Japanese sake as well as international initiatives being planned by JSS.
Representatives from sommelier associations around the world provided a broad range of feedback on how sake could be paired with various styles of cuisines, with many expressing that they would like to try sake with their own country’s culinary specialties.
The reception featured an eight-course meal fusing French cuisine with dashi-inspired flavors and paired with eight local brands of sake, in an ensemble featuring Mie’s three local specialties—ingredients, dashi and sake. This level of hospitality proved to be a source of amazement and inspiration for the leading international sommeliers who had the chance to savor the flavors provided.
The chairs of the Belgian, Serbian, Spanish, and Mexican sommelier associations expressed their desire to work with JSS and schedule sake master classes in the near feature, thus demonstrating the considerable interest that sommeliers have developed for sake.
Looking forward, JSS will coordinate efforts with ASI by providing sake tasting and seminars at events organized by ASI.
Japan Sake and Shochu Makers Association SNS links are as follows.
FB: https://www.facebook.com/japansakeshochu
IG: https://www.instagram.com/japansakeshochu_en/
YouTube: https://www.youtube.com/user/JapanSakeOfficial
Twitter: https://twitter.com/jss_sake_en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005658/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
